Discovery Laboratories, Inc. is a biotechnology company focused on creating life-saving products for critical care patients with respiratory disease. The Company�s produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival. In addition, its capillary aerosol-generating technology produces a dense aerosol with a defined particle size, to deliver its aerosolized KL4 surfactant to the lung. It is developing its products, Surfaxin(lucinactant), Surfaxin LS and Aerosurf, to address the respiratory conditions affecting neonatal populations. It has filed a New Drug Application (NDA) for its product based on its KL4 surfactant technology, Surfaxin for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. It focuses on manufacturing three additional Surfaxin batches for use in the preclinical program.